AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

BridgeBio Pharma Inc. (BBIO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

35.67

0.77 (2.21%)

At close: Feb 18, 2025, 3:59 PM

35.55

-0.35%

After-hours: Feb 18, 2025, 07:16 PM EST

undefined% (undefined)

Bid	35.55
Market Cap	6.74B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.42
PE Ratio (ttm)	-14.74
Forward PE	n/a
Analyst	Buy

Ask	36.24
Volume	3,127,406
Avg. Volume (20D)	2,510,318
Open	34.91
Previous Close	34.90
Day's Range	33.86 - 36.07
52-Week Range	21.62 - 37.81
Beta	undefined

About BBIO

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-car...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 27, 2019

Employees 550

Stock Exchange NASDAQ

Ticker Symbol BBIO

Website https://www.bridgebio.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is $46.5, which is an increase of 30.34% from the latest price.

Buy 91.67%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

BridgeBio Pharma Inc. is scheduled to release its earnings on Feb 20, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+16.1%

BridgeBio Pharma shares are trading higher after t... Unlock content with Pro Subscription

3 months ago

-5.74%

BridgeBio Pharma shares are trading lower after the company reported mixed Q3 financial results.

News

1 month ago · seekingalpha.com

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

Attruby's recent approval positions BBIO as a direct competitor to PFE's Vyndaqel in ATTR-CM. Attruby has a 42% reduction of heart failure risk with 90% TTR stabilization. So I think it could have a s...

1 month ago · youtube.com

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

BridgeBio CEO Neil Kumar joins CNBC's 'Power Lunch' to discuss the company's latest drug developments, how the drugs compares to competitors in the space, and more.

1 month ago · zacks.com

Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength?

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc...

1 month ago · investors.com

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.

2 months ago · zacks.com

BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

2 months ago · benzinga.com

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

On Friday, the FDA approved BridgeBio Pharma, Inc.'s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiova...

2 months ago · seekingalpha.com

BridgeBio: Next Chapter Begins After Attruby Approval

BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also t...

2 months ago · reuters.com

US FDA approves BridgeBio's drug for rare heart condition

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer...

3 months ago · benzinga.com

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions...